메인으로

Notable Achievements

This is ONCOBIX's ongoing journey toward becoming a global pharmaceutical company for drug discovery.

  • home icon

ABOUT US

This is ONCOBIX's ongoing journey toward becoming a global pharmaceutical company for drug discovery.

2021 ~ Present

  • - Preclinical study evaluation completed
  • - Nonclinical trial preparation
  • - License-out and collaborative research with Dong-A ST
  • - Selected for government-supported research hospital programs
  • - 2 new patents pending
  • - Patents registered in U.S., Russia, and Australia
  • - Named among Baby Unicorns 200
  • - Bridge round completed
  • - Nonclinical toxicology evaluation completed
  • - Phase I and II preparations for IND
  • - Collaborative research agreement with SK Chemicals, HK InnoN, Samjin Pharmaceutical

2019 ~ 2020

  • - Series A
  • - Second-generation platform technology developed
  • - GLP toxicology studies
  • - 2 patent registrations, entering 9 countries
  • - Agreements with domestic and international pharmaceutical companies

2017 ~ 2018

  • - Enterprise Laboratory certification earned
  • - First-generation platform technology developed
  • - Venture enterprise certified
  • - Research collaboration contract signed with Asan Medical Center, Seoul

2016

  • - ONCOBIX Inc. established

회원로그인

회원가입